Matched TA-TAVR patients experienced more adverse procedural events , longer length of stay ( 5 versus 8 days ; P < 0.0001 ) , and slower recovery ( New York Heart Association class I , 31 % versus 38 % at 30 days , equalizing by 6 months at 51 % versus 47 % ) ; stroke risk was similar ( 3.4 % versus 3.3 % at 30 days and 6.0 % versus 6.7 % at 3 years ) ; mortality was elevated for the first 6 postprocedural months ( 19 % versus 12 % ; P = 0.01 ) ; but aortic regurgitation was less ( 34 % versus 52 % mild and 8.9 % versus 12 % moderate to severe at discharge , P = 0.001 ; 36 % versus 50 % mild and 10 % versus 15 % moderate to severe at 6 months , P < 0.0001 ) .